Mumps Research - Symptoms, Vaccine, Adult, Causes

Mumps Research Today is a free monthly online journal that collates and summarizes the latest research about Mumps, including details on symptoms, vaccine, adult, causes.


Mumps Research Today

Home

View Latest Issue

Information About Mumps

Books on Mumps

Advertising in Research Today

View Other Research Today Publications



Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein.

Reyes-Leyva J, Baños R, Borraz-Argüello M, Santos-López G, Rosas N, Alvarado G, Herrera I, Vallejo V, Tapia-Ramírez J

Laboratorio de Virología y Biología Molecular, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social; Hospital General de Zona No. 5, Km. 4.5, Carretera Atlixco-Metepec, 74360 Metepec, Puebla, Mexico.

A mutation coding for the amino acid change E(335) to K is frequently found in the hemagglutinin-neuraminidase (HN) gene of Urabe AM9 mumps viruses isolated during post-vaccination meningitis cases. To identify if this mutation modifies the biological activities of the HN glycoprotein, two variants of Urabe AM9 vaccine differing at amino acid 335 (HN-E(335) and HN-K(335)) were isolated and their receptor-binding specificity was determined by means of competence assays. Pre-incubation of the viruses with sialic acids inhibited both syncytia formation in Vero cells and replication in SH-SY5Y cells. Thus, HN-K(335) showed higher affinity towards sialylalpha2,6lactose, whereas HN-G(335) preferred sialylalpha2,3lactose. These results are relevant because a high expression of sialylalpha2,6lactose in nerve cells was confirmed by means of Sambucus nigra lectin-cytochemistry. In addition, kinetics assays showed that HN-K(335) and HN-E(335) also differ in their hydrolysis rate (V(max) values of 37.5 vs. 3.5nmolmin(-1)mg(-1), respectively). Therefore, HN-K(335) variant presented a neuraminidase activity level 11-fold higher than that of HN-E(335) variant. In conclusion, the mutation affects the receptor-binding and neuraminidase activities of Urabe AM9 mumps virus variants.

Published 16 February 2007 in Microbes Infect, 9(2): 234-40.
Full-text of this article is available online (may require subscription).

Place a permanent text-link or advertisement here for just US$15.

© 2004-2008 Mumps Research Today. All Rights Reserved.



Mumps Research Today Archive:

Volume 1 (2004)
  Issue 1 (November)
  Issue 2 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)



Mumps Books

DNA-Pharmaceuticals: Formulation and Delivery in Gene Therapy, DNA Vaccination and Immunotherapy

DNA-Pharmaceuticals: Formulation and Delivery in Gene Therapy, DNA Vaccination and Immunotherapy